Aims: This study compares the impact of pneumothorax and pneumomediastinum on the mortality and morbidity of respiratory viral infection patients using blood parameters and the Systemic Immune Inflammation Index (SII) among those who developed these complications versus those who did not.
This study examines the effects of pneumothorax and pneumomediastinum on the mortality and morbidity of patients with respiratory virus infections. It analyses blood parameters and the Systemic Immune Inflammation Index (SII) in patients who acquired these complications compared to those who did not.
Methods: A retrospective evaluation of 2246 COVID-19 patients treated in our medical facility from August 2020 to February 2021 was performed. The investigation comprised 118 patients hospitalized owing to the respiratory viral infection in this cohort. Patients were divided into two groups: those who had pneumothorax and/or pneumomediastinum and those who did not develop these problems, with equal representation in each. The study examined criteria such as metabolic profiles, hemogram results, length of hospital stay, SII levels, and the incidence of pneumothorax, with an emphasis on their relationship to morbidity and mortality outcomes.
We conducted a retrospective assessment of 2246 COVID-19 patients who received treatment at our medical facility between August 2020 and February 2021. This study included a total of 118 patients who were admitted to the hospital due to a respiratory virus illness. The patients were categorised into two groups: one consisting of individuals who experienced pneumothorax and/or pneumomediastinum, and the other consisting of individuals who did not acquire these complications. Both groups had an equal number of participants. The study analysed many factors including metabolic profiles, hemogram results, length of hospital stay, SII levels, and the incidence of pneumothorax, with a focus on their association with morbidity and mortality outcomes.
Results: Notably, female patients who developed pneumothorax while receiving COVID-19 therapy had a higher fatality rate. Patients that had pneumothorax also had raised leukocyte and neutrophil counts, as well as increased SII and lower total protein and albumin levels. These data underscore the potential significance of particular blood measures, along with the occurrence of pneumothorax, as indicators for mortality in patients with respiratory viral infections.
Significantly, female patients who experienced pneumothorax during COVID-19 treatment exhibited a worse mortality rate. Patients with pneumothorax had elevated leukocyte and neutrophil counts, along with heightened systemic immune-inflammation index (SII) and decreased levels of total protein and albumin. The data highlight the potential importance of specific blood measurements, as well as the presence of pneumothorax, as indications for death in patients with respiratory virus infections.
Conclusions: To improve patient outcomes, female patients who develop pneumothorax following respiratory viral Infection treatment should be closely monitored and managed.
For enhanced patient outcomes, it is important to closely monitor and manage female patients who get pneumothorax after receiving therapy for respiratory virus infection.
Key words: complications, mortality, pneumomediastinum, pneumothorax, thorax
|
